CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Zentalis Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Zentalis Pharmaceuticals Inc
10275 Science Center Drive, Suite 200
Phone: (858) 263-4333p:858 263-4333 SAN DIEGO, CA  92121  United States Ticker: ZNTLZNTL
Business Summary
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is engaged in developing azenosertib (ZN-c3), a potentially first-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. The inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death and thereby preventing tumor growth and potentially causing tumor regression. WEE1 acts as a regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202412/31/2024YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board ScottMyers 11/13/2024 11/13/2024
President, Chief Executive Officer, Director JulieEastland 60 11/13/2024 11/13/2024
Senior Vice President, Finance, Interim Principal Accounting Officer and Principal Financial Office VincentVultaggio 42 11/13/2024 11/13/2024
9 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Zeno Management, Inc. 10275 Science Center Dr San Diego CA United States

Business Names
Business Name
K-Group Alpha, Inc.
K-Group Beta, Inc.
Zeno Alpha, Inc.
4 additional Business Names available in full report.

General Information
Number of Employees: 166 (As of 12/31/2024)
Outstanding Shares: 71,811,508 (As of 3/21/2025)
Shareholders: 9
Stock Exchange: NASD
Federal Tax Id: 823607803
Fax Number: (302) 655-5049


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 19, 2025